Document is current
Any future updates will be listed below
-
Authors
Tauveron-Jalenques, Urbain https://orcid.org/0009-0007-1486-9873
Aspas Requena, Gaspar https://orcid.org/0000-0001-9033-575X
Gross, Zofia
Tavernier, Emmanuelle https://orcid.org/0000-0002-1447-8721
Chorão, Pedro https://orcid.org/0000-0001-6741-971X
Carre, Martin
Cornillon, Jérôme
Contejean, Adrien
Santana, Clémence
Rocher, Clément
Lamure, Sylvain
Mauz, Natacha
Thevenet, Ugo
Boullanger, Nadine
Pica, Gian Matteo
Dony, Arthur
Michallet, Mauricette https://orcid.org/0000-0002-7338-1081
Belhabri, Amine
Heiblig, Maël
- License Information
-
More Information
Article History
Received: 1 October 2025
Revised: 26 January 2026
Accepted: 9 March 2026
First Online: 24 March 2026
Competing interests
: Emmanuelle Tavernier, Martin Carré, Jérôme Cornillon, Sylvain Lamure: honoraria for advisory boards (AbbVie). Adrien Contejean: grants (Janssen, BMS, AbbVie), support for attending meetings (Pfizer, Servier). Clément Rocher: honoraria for advisory boards (BMS), symposia (GSK), and staff (AstraZeneca). Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Zofia Gross, Pedro Chorão, Clémence Santana, Natacha Mauz, Ugo Thevenet, Nadine Boullanger, Gian Matteo Pica, Arthur Dony, Mauricette Michallet, Amine Belhabri and Maël Heiblig declare no potential competing interests.
